Advertisement


Lisa A. Carey, MD, and Nadia Harbeck, MD, PhD, on Early HER2-Negative Breast Cancer: Results of the PlanB Trial

2017 ASCO Annual Meeting

Advertisement

Lisa A. Carey, MD, of the University of North Carolina, and Nadia Harbeck, MD, PhD, of Brustzentrum der Universität München, discuss study findings on adjuvant 4xEC→4x doc vs 6x docetaxel/cyclophosphamide in patients with high clinical risk and intermediate-to-high genomic risk HER2-negative, early breast cancer. (Abstract 504)



Related Videos

Breast Cancer

Lisa A. Carey, MD, and Richard S. Finn, MD, on Breast Cancer: Findings From the PALOMA-1/TRIO 18 Trial

Lisa A. Carey, MD, of the University of North Carolina, and Richard S. Finn, MD, of UCLA Medical Center, discuss phase II overall survival findings on palbociclib in combination wi...

Issues in Oncology

Elizabeth J. Shpall, MD, and Nina Shah, MD—Mentor and Mentee: A Conversation

Elizabeth J. Shpall, MD, of The University of Texas MD Anderson Cancer Center, and recipient of the 2017 Women Who Conquer Cancer Mentorship Award, discusses promoting women in onc...

Breast Cancer

Gunter von Minckwitz, MD, on HER2+ Breast Cancer: Results From the APHINITY Trial

Gunter von Minckwitz, MD, of the German Breast Group, discusses study findings on a randomized comparison of chemotherapy, trastuzumab, and placebo vs chemotherapy, trastuzumab, an...

Bruce E. Johnson, MD, and Julie Vose, MD, MBA: A Conversation With ASCO’s 2017–2018 President

Julie Vose, MD, MBA, of the University of Nebraska Medical Center, and Bruce E. Johnson, MD, of the Lowe Center for Thoracic Oncology at Dana-Farber Cancer Institu...

Hepatobiliary Cancer

John Marshall, MD, and John Neil Primrose, PhD, MBBS, on Biliary Tract Cancer: Results From the BILCAP Trial

John Marshall, MD, of Georgetown University, and John Neil Primrose, PhD, MBBS, of the University of Southampton, discuss the potentially practice-changing finding...

Advertisement

Advertisement



Advertisement